Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company leveraging artificial intelligence (AI) and machine learning, has announced it will host a webcast on Aug. 14, 2026, at 9 a.m. ET to discuss its second-quarter 2026 operating and financial results. President and CEO Panna Sharma, joined by members of the management team, will review results for the quarter ended June 30, 2026, and provide updates on upcoming milestones, clinical trials, and developments involving the company’s RADR(R) and Open-Medicine AI platforms. A webcast replay will be available through the investor relations section of Lantern Pharma’s website following the event.
The announcement comes as Lantern Pharma continues to integrate AI across its oncology pipeline, with a focus on accelerating drug development and reducing costs. The company’s proprietary RADR platform, which stands for “Response Algorithm for Drug Repositioning,” uses AI to analyze genomic and clinical data to identify patient populations most likely to respond to its therapies. This approach is central to Lantern’s strategy of developing precision medicines for cancers with high unmet medical need.
Lantern’s clinical pipeline includes LP-184, an acylfulvene compound being developed for multiple solid tumors, including pancreatic cancer and glioblastoma. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. Another candidate, LP-284, is a TC-NER targeting compound aimed at hematologic and solid tumors. Additionally, LP-300, a cisplatin/ethacraplatin analog, is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. These programs highlight Lantern’s commitment to targeting difficult-to-treat cancers with biomarker-driven approaches.
Beyond its clinical pipeline, Lantern has made strides in commercializing its AI capabilities. The company’s withZeta.ai platform, a multi-agentic AI co-scientist, is now commercially available as a subscription-based research platform for the global biomedical and drug development community. This represents a new revenue stream for Lantern, diversifying its business model beyond drug development. The platform is designed to assist researchers in hypothesis generation, experimental design, and data analysis, potentially reducing the time and cost of drug discovery.
Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company’s focus on AI-driven drug development aligns with broader industry trends towards personalized medicine and digital transformation. By leveraging AI to identify patient subgroups that are more likely to respond to its drugs, Lantern aims to improve clinical trial success rates and bring therapies to market more efficiently.
The upcoming webcast will provide investors with insights into the company’s financial performance and strategic direction. Key areas of focus will likely include progress on clinical trials, updates on the withZeta.ai commercial rollout, and any new partnerships or collaborations. As Lantern continues to advance its pipeline and expand its AI offerings, the company is positioning itself at the forefront of precision oncology, with the potential to transform cancer treatment paradigms.
For more information, visit https://ibn.fm/l80kv to view the full press release.
